John Öhd,
The fourth quarter in figures
- The loss after tax amounted to TSEK 12 289 (1 019).
-
The loss per share amounted to
SEK 0,76 (0,12). - The cash flow from current operations was negative in the amount of TSEK 8 387 (1 107).
The full year in figures
- The loss after tax amounted to TSEK 20 691 (6 019).
-
The loss per share amounted to
SEK 1,67 (1,12). - The cash flow from current operations was negative in the amount of TSEK 16 078 (7 231).
- Cash and cash equivalents amounted to TSEK 20 648 (7 345).
Important events during the quarter
- Symbiosis Pharmaceutical Services starts producing sevuparin for Modus' future clinical development in sepsis/septic shock.
Modus Therapeutics engages Lago Kapital as a liquidity guarantor.-
Modus Therapeutics Receives Regulatory Approval to Start Phase 1b Clinical LPS Challenge Study with Sevuparin in
the Netherlands . - First subject was dosed in the Phase 1b Clinical LPS Challenge Study.
Important events after the end of the period
No event to report.
The year-end report will also be presented at an investor webcast today
This information is such information that
For more information on
John Öhd, VD,
Telefon: +46 (0) 70 766 80 97
E-post: john.ohd@modustx.com
Certified Adviser
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
About
Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested - an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.
https://news.cision.com/modus-therapeutics/r/modus-therapeutics-publishes-year-end-report-for-2021,c3511101
https://mb.cision.com/Main/20380/3511101/1538584.pdf
(c) 2022 Cision. All rights reserved., source